Metabomed

Nanobiotix Corp is a biotechnology company based in Cambridge, MA that specializes in the development of innovative cancer therapies. They have recently achieved a significant $20 million development milestone payment for their ongoing global Phase 3 Head and Neck Cancer Study, and have also raised $55 million through a capital increase. With a strong focus on research and development, Nanobiotix is dedicated to advancing their science pipeline and collaborating with partners to bring effective treatments to patients. Through their cutting-edge technology, Nanobiotix aims to revolutionize cancer treatment by leveraging nanomedicine to enhance the efficacy of radiation therapy. Their preliminary results from Phase 1 trials in pancreatic cancer and head and neck cancer have shown promising outcomes, further highlighting their commitment to improving patient outcomes. With a dedicated team of leaders, a scientific advisory board, and a strong presence in the media and investor community, Nanobiotix is poised to make a significant impact in the field of oncology.Generated from the website

Adaptimmune is a Cambridge-based company dedicated to revolutionizing the treatment of solid tumor cancers. Utilizing a proprietary cell therapy platform, they engineer a patient's own cells to combat their cancer, offering a personalized approach that has the potential to significantly improve the patient experience. With their first Biologics License Application (BLA) submitted to the FDA, Adaptimmune is on the cusp of a new era in cancer treatment. Their goal is to commercialize the first engineered T-cell therapy for solid tumors, aiming to reshape the landscape of cancer care with a single infusion.Generated from the website

Epizyme is a global biopharmaceutical company based in Cambridge, MA, dedicated to improving patients' lives through research, innovation, and the development of transformative medicines in Oncology, Rare Disease, and Neuroscience. With a focus on areas of high unmet medical need, Epizyme is accelerating its momentum and rapidly expanding its pipeline to bring the full potential of its innovative medicines to patients. Guided by patient outcomes and supported by a culture of collaboration and excellence, Epizyme leverages its global reach and R&D firepower to partner with like-minded innovators and develop the next generation of medicines. With a strong track record in commercializing its medicines and a commitment to making a real impact for people living with high unmet medical needs, Epizyme is a leader in its field, leveraging its infrastructure, innovation, and passion to develop new therapies and valuable collaborations.Generated from the website